Mylan Inc. Nov. 8 said it had settled patent litigation with Janssen Pharmaceuticals Inc. related to Mylan’s bid to sell a generic version of the contraceptive pill Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol tablets) (Janssen Pharmaceuticals Inc. v. Mylan Inc.).
Under the settlement, which also includes Famy Care Ltd., Mylan will be licensed to sell its norgestimate/ethinyl estradiol Tablets 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg, on Dec. 31, 2015, or earlier under certain circumstances.
In 2008, Mylan and Indian company Famy Care entered into a partnership to develop and supply oral contraceptives (6 PLIR 948, 8/15/08
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.